Forte Biosciences (NASDAQ:FBRX) shares surged about 40% to around $76 on Monday after argenx (NASDAQ:ARGX) announced an agreement to acquire the biotechnology company in a deal valued at approximately $2.2 billion. Under the terms of the agreement, argenx will acquire all outstanding Forte Biosciences shares for $77 per share in cash.
Forte Biosciences stock soars after early-stage data show FB102 significantly improves facial depigmentation in vitiligo with a favorable safety profile.
Forte Biosciences NASDAQ: FBRX said FB102 showed statistically significant improvement in a small placebo-controlled vitiligo study, with Chief Executive Officer Paul Wagner highlighting continued improvement after patients stopped treatment as a key feature of the results.
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| NA Nizar Araji National Bank Of Canada /FI/ | 572 | $14,488.4 | $43,923.88 | $29,435.48 | 203.17% |
Joseph Castro Nuveen LLC | 108,347 | $2.3M | $8.32M | $6.02M | 261.51% |
Li Peng China Universal Asset Management Co. Ltd. | 8,000 | $170,560 | $612,800 | $442,240 | 259.29% |
Hui Fai Tam Caitong International Asset Management Co. Ltd. | 113 | $2,401 | $8,656.93 | $6,255.93 | 260.56% |
Mark Schafer Police & Firemen's Retirement System of New Jersey | 5,712 | $121,380 | $437,539.2 | $316,159.2 | 260.47% |
| Biotechnology Industry | Healthcare Sector | Paul A. Wagner CEO | NASDAQ (CM) Exchange | 34962G208 CUSIP |
| US Country | 23 Employees | 16 Jun 2020 Last Dividend | 28 Aug 2024 Last Split | - IPO Date |